Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cholesterol/Lipid Disorders
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cholesterol/Lipid Disorders
    Atorvastatin Improves Dyslipidaemia in Patients With Coronary Heart Disease, May Be Renoprotective: Presented at Renal Week 2009 - (DGDispatch)
    Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents - (JAMA)
    TopAbstracts in Cholesterol/Lipid Disorders 10/29/2009 - (DGNews)
    Addition of Ezetimibe Helps More Elderly Achieve LDL Cholesterol Goal Than Uptitration of Atorvastatin: Presented at CCC - (DGDispatch)
    New Canadian Cholesterol-Lowering Guidelines Target Immediate-Risk Group: Presented at CCC - (DGDispatch)

    News archive

     Recent webcasts/CME - Cholesterol/Lipid Disorders
    • Optimizing Management of Dyslipidemia: Risk Assessment, Treatment Targets, and Adherence
    • Assessing Cardiovascular Risk
    • Setting Treatment Goals for Primary Prevention of Cardiovascular Disease
    • Diabetes Management - Pearls of Lipid Control
      Initiating and Monitoring Statin Therapy

      Webcasts/CME archive

       Recent cases - Cholesterol/Lipid Disorders
        There May be a Link Between Intrahepatic Cholestasis of Pregnancy and Familial Combined Hyperlipidaemia: A Case Report
        Marked Aortic Valve Stenosis Progression After Receiving Long-Term Aggressive Cholesterol-Lowering Therapy Using Low-Density Lipoprotein Apheresis in a Patient With Familial Hypercholesterolemia
        Acute Myocardial Infarction in an 18 Year Old South Indian Girl with Familial Hypercholesterolemia: A Case Report
        Eruptive Xanthomas and Acute Pancreatitis in a Patient with Hypertriglyceridemia
        Abetalipoproteinemia: Two Case Reports and a Literature Review

        Cases archive
          




        my personal edition > cholesterol/lipid disorders > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Direct Comparison Shows Rosuvastatin Achieves Greater Reductions Than Atorvastatin in LDL-C: Presented at CCC

        By Danny Kucharsky

        MONTREAL, CANADA -- October 27, 2005 -- Rosuvastatin 10 mg provides a broader benefit to the entire lipid profile than does atorvastatin 10 mg in a high- to very-high-risk patient population, a study presented at the Canadian Cardiovascular Society Congress 2005 (CCC) has found.

        The Discovery-Canada study compared the efficacy of rosuvastatin with atorvastatin in achieving Canadian and European lipid goals after 12 weeks in patients with hypercholesterolemia.

        Eligible patients from 177 centres entered a 2-week run-in period, followed by open-label randomisation to rosuvastatin 10 mg or atorvastatin 10 mg once daily for 12 weeks. A total of 2009 patients were randomised and 1917 were evaluable for efficacy.

        Of the 1917 patients, 1289 were treated with rosuvastatin and 628 with atorvastatin, said lead investigator Christian Constance, MD, cardiologist, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada, during his presentation here on October 26th.

        At week 12, the rosuvastatin arm had a 43.6% decrease in low-density lipoprotein (LDL) cholesterol compared with 34.9% in the atorvastatin 10-mg group. High-density lipoprotein (HDL) cholesterol increased by 4.4% in the rosuvastatin group and by 2.2% in the atorvastatin group (P < .0001).

        The researchers observed similar LDL decreases in statin-naive patients in the 2 treatment groups. As well, 53.9% of rosuvastatin patients achieved an LDL goal of < 2.0 mmol/L, compared with 29.8% of atorvastatin patients (P < .0001).

        Adverse events were similar between the 2 groups, with no reported incidences of rhabdomyolysis in either treatment group.

        Rosuvastatin "is highly efficacious at modifying the lipid profile and may improve the likelihood of reaching lipid goals," Dr. Constance concluded.


        [Presentation title: Direct Statin Comparison of LDL-C Values: An Evaluation of Rosuvastatin Therapy (Discovery -- Canada). Abstract 490]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send